AKTX
Akari Therapeutics plc ADR (0.01 USD)
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
AKTX Stock Analysis: Buy, Sell, or Hold?
$6.51
-0.94 (-12.62%)
▼
5d:
-16.0%
30d:
-10.58%
90d:
-13.66%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (77%)
Quality Score
38/100
Position
OVERSOLD
30-Day Fair Range
$7.50 – $8.96
Position: OVERSOLD
Forward P/E & Valuation
-0.8x
Next 12M consensus est.
Wall Street Target
$25.50
+291.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.51 / $9.38
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: AKTX is down 16.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When AKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: AKTX is currently trading at $6.51, which is considered oversold relative to its 30-day fair value range of $7.50 to $8.96.
Technical Outlook: Technically, AKTX is in a downtrend. The price is currently testing key support at $6.51. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.50 (+291.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKTX is in a downtrend. The price is currently testing key support at $6.51. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.6% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.50 (+291.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.50 -
$8.96
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
Trading Range & Key Levels
30-Day Trading Range
$7.50 -
$8.96
Current vs Trading Range
OVERSOLD
Support Level
$6.51
Resistance Level
$9.38
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.6%)
- BULLISH: Trading 291.7% below Wall St target ($25.50)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-0.75
Wall Street Target
$25.50
(+291.7%)
Share AKTX Analysis
Share this live AKTX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 12, 2026 6:56 PM ET
Data refreshes hourly during market hours. Next update: 7:56 PM
Data refreshes hourly during market hours. Next update: 7:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive AKTX Research Pages
